DR HASANPASHA SHOLAPUR
@klecoph.edu.in
ASSISTANT PROFESSOR, DEPARTMENT OF PHARMACOGNOSY
KLE COLLEGE OF PHARMACY, HUBLI
EDUCATION
M.Pharm., (
RESEARCH INTERESTS
Extraction, Isolation, Characterization of Phytochemicals and their formulations , Plant Tissue Culture
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Revati Dharampal Sagare, Fatima Sanjeri Dasankoppa, Hasanpasha N. Sholapur, N.R. Banapurmath, and M.A. Umarfarooq
Elsevier BV
Revati Dharampal Sagare, Fatima Sanjeri Dasankoppa, and Hasanpasha N. Sholapur
Springer Science and Business Media LLC
Hasanpasha N. Sholapur, Basanagouda M. Patil, and Fatima Sanjeri Dasankoppa
Informa UK Limited
REVATI DHARAMPAL SAGARE
Societatea de Stiinte Farmaceutice din Romania
Halloysite nanotubes (HNTs) have several exciting potential applications in polymer nanocomposites. These are naturally sourced nanomaterials obtained from the mines as a natural deposit. The hollow tubular nanostructure with biocompatibility, environmental friendly and low-cost possessing makes halloysite as trendsetter in green nanotechnology. These are composed of double-layered, aluminosilicate minerals with an ultra-tiny hollow tubular structure in submicron range. The specific characteristics of HNTs lead to plentiful range of applications in environmental sciences, dye removal, anticorrosive coatings, in cosmetics, flame retardants, forensic science, etc. HNTs display remarkable thermal stability, faster adsorption rates, tuneable release rates, excellent drug encapsulation, biocompatibility, mechanical properties and ease of availability, therefore with numerous pharmaceutical applications. Nanomedical applications are gene delivery, tissue engineering, cancer and stem cells isolation and bio-imaging. This review is focused on the detailing HNTs for its structure features, functionalization methods, drug loading and their versatile applications.
Hasanpasha N Sholapur and Basanagouda M Patil
EManuscript Technologies
Objective: Alcoholic extract of the bark of Moringa oleifera Lam. (MO), (Moringaceae), has been experimentally evaluated previously for its insulin sensitizing potentials. In the quest to explore the possibility of the class of phytochemical(s) responsible for this experimental claim, the alcoholic extract was fractionated and evaluated for insulin sensitizing effect in rat model for insulin resistance. Methods: Alcoholic extract of MO was fractionated into, non-polar [petroleum ether (PEF)], moderately non-polar [ethyl acetate (EAF)] and polar [aqueous (AQF)] fractions. The fractions obtained were investigated for their insulin sensitizing properties in dexamethasone induced insulin resistance in rats. The bioactive fraction was analysed by spectroscopy for further characterization of phytochemical(s) present. Results: Acute treatment for 4 h with dexamethasone (1 mg/kg i.p.) in rats led to the development of impaired oral glucose tolerance. Treatment with pioglitazone and EAF abolished dexamethasone induced oral glucose intolerance (OGT). Dexamethasone (1 mg/kg s.c., once daily for 11 d) administration led to the development of insulin resistance, characterised by fasting hyperglycemia, hyperinsulinemia, hypertriglyceridemia, impaired OGT and increased HOMA IR index. Treatments with EAF (140 mg/kg p.o.) and pioglitazone [PIO (10 mg/kg p.o.)] significantly prevented dexamethasone induced metabolic changes. Similarly, treatment with AQF (95 mg/kg p.o.) also significantly prevented metabolic changes due to dexamethasone except impaired OGT. In contrast PEF (15 mg/kg p.o.) failed to prevent these metabolic changes except hypertriglyceridemia. Conclusion: The present study reveals that triterpenoid and the polyphenols (procyanidin) class of phytochemicals detected in EAF of alcoholic extract of MO bark may be responsible for the prevention of dexamethasoneinduced insulin resistance in rats. Key words: Dexamethasone, Insulin resistance, Moringa oleifera , Oral glucose tolerance test, Serum triglyceride.
Fatima Sanjeri Dasankoppa, Vinuta Mallikarjun Sajjanar, Hasanpasha Sholapur, N.G. Nanjundaswamy, Kiran Ashok Kubasad, and Pooja Mohan Walvekar
EManuscript Technologies
Background: Rosuvastatin calcium exhibits poor oral bioavailability due to extensive pre-systemic metabolism. Orodispersible tablets (ODTs) were prepared that disintegrate rapidly in oral mucosa thus preventing presystemic metabolism and enhancing the bioavailability of the drug. Objective: The objective of this study was to employ SeDeM ODT Expert system for characterization of excipients and formulation development of orodispersible tablets of rosuvastatin calcium. Materials and methods: ODTs were prepared by direct compression method using starlac as diluent and lycatab C and crospovidone as superdisintegrants in different concentrations. SeDeM ODT expert system was used on the excipients to predict their suitability for direct compression method. Results: SeDeM ODT expert system employed revealed that starlac, lycatab C and crospovidone were suitable and xylitol and sodium starch glycolate were unsuitable for direct compression method. FTIR studies revealed that there was no physico-chemical interaction between drug and other excipients. Preformulation studies were carried out to study the powder flow characteristics in order to achieve tablets of uniform weight. The values were well within the permissible limits. The tablets were subjected to post formulation evaluation parameters like thickness, weight variation, hardness, friability, wetting time, water absorption ratio, drug content uniformity, in vitro disintegration and in vitro dissolution studies. Conclusion: Suitability of the material for direct compression was successfully predicted using the SeDeM expert system. Formulations were developed based on the results of the SeDeM ODT expert system. Formulation F3 containing 15%w/w lycatab C as superdisintegrant exhibited minimum disintegration time and wetting time of 14.02±0.151s and 12.31±0.139s respectively and a maximum cumulative drug release of 93.06% at 15min. Hence, F3 formulation was the optimized formulation subjected to stability studies. Stability studies revealed that the formulation F3 was stable when stored at 40±2°C/75±5%RH for one month. Key words: Direct compression, Lycatab C, Orodispersible tablets, Se- DeM ODT Expert system, Starlac, Crospovidone.
Komal S, F S Dasankoppa, H N Sholapur, N G N Swamy, and V. Sajjanar
OMICS Publishing Group
Ion exchange resins are water-insoluble, cross-linked polymers containing salt forming groups in repeating positions on the polymer chain. Bitter cationic drugs get adsorbed on to weak cationic exchange resins of carboxylic acid functionally like Indion 204, Indion 234 and Tulsion 335 to forms the non-bitter complexes. The present investigation aims at taste masking of bitter clarithromycin using ion exchange resins, which forms complexes, inhibiting its release in saliva. The drug resin complex loading process was optimized for the content of resin, activation, swelling time, stirring time, influence of pH and temperature for maximum drug loading and were subjected to differential scanning calorimetry to confirm the complex formation. These complexes were used to prepare chewable tablets and statistically the taste was evaluated. Acid activated resins comprising of Indion 204, Indion 234 and Tulsion 335 with drug: resin ratio of 1:2, stirred in solution of pH 7-8 at 70o for 6 h had a maximum drug loading and masked the bitter taste of the drug. Differential scanning calorimetry of drug resin complex revealed that there was interaction leading to complex formation. Drug resin complex were formulated into chewable tablet formulations (F1-F9) and evaluated. The various pre-compression and post parameters were found to be within permissible limits. Formulations F3, F6 and F9 containing 1:2 ratios of drug resin complex of Indion 204, Indion 234 and Tulsion 335 revealed maximum taste masking. This was further confirmed by treatment of taste evaluation scores of the volunteers by ANOVA, Dunnet multiple comparison test and Tukey’s multiple comparison test. All the three optimized formulations had a significant difference of P<0.001 when compared to control F10. F6 formulation was widely accepted. Ion exchange complexation could efficiently mask the bitter taste of clarithromycin and achieve palatable taste suitable for pediatric use.
H. Sholapur and B. Patil
Georg Thieme Verlag KG
BACKGROUND
Experimental study has revealed the antidiabetic potentials of ethanolic extract of the bark of Moringa oleifera Lam., (Moringaceae), a multipurpose tree of south Asia.
OBJECTIVE
To investigate the effects of alcoholic and petroleum ether extracts of Moringa oleifera bark on acute and chronic insulin resistance induced by dexamethasone in rats.
MATERIALS AND METHODS
Dexamethasone (dexa) was administered for 11 days (1 mg/kg, s. c., once daily) and single dose (1 mg/kg, i. p.) to induce chronic and acute insulin resistance respectively. 2 doses each of alcoholic (AE125 and AE250 mg/kg) and petroleum ether extracts (PEE30 and PEE60 mg/kg) and single dose each of alcoholic (AE250 mg/kg) and petroleum ether extract (PEE 60 mg/kg) of Moringa oleifera bark were tested in chronic and acute studies. At the end of the studies fasting plasma glucose, triglyceride levels and oral glucose tolerance were measured.
RESULTS
In chronic study, treatment of rats with AE125 and AE250 prevented dexamethasone-induced hypertriglyceridemia and oral glucose intolerance but not fasting hyperglycemia, whereas both PEE30 and PEE60 had no effects on any of these parameters measured except that significant reduction of triglyceride level was observed in PEE60 treated rats. Oral glucose intolerance induced by single dose administration of dexamethasone was prevented by AE250 but not by PEE60. In normal rats AE250 treatment improved the glucose tolerance, where as PEE60 had no effect on this parameter.
CONCLUSION
The present study indicates that AE of Moringa oleifera prevents dexamethasone-induced insulin resistance in peripheral tissues.
Shivanand Swamy P. Hiremath
MDPI AG
Abstract A major problem in ocular therapeutics is the attainment of optimal drug concentration at the site of action, which is compromised mainly due to precorneal loss resulting in only a small fraction of the drug being ocularly absorbed [1]. The effective dose administered may be altered by increasing the retention time of medication into the eye by using in situ gel forming systems. The aim of the present investigation is to prepare and evaluate novel in situ gum based ophthalmic drug delivery system of linezolid. Hydroxypropyl guar (HPG) and xanthum (XG) were used as gum with the combination of hydroxyethyl cellulose (HEC), carbopol (CP), and sodium alginate as viscosity enhancing agents. Suitable concentrations of buffering agents were used to adjust the pH to 7.4. All the formulations were sterilized in an autoclave at 121°C for 15mins. The formulations were evaluated for clarity, pH measurement, gelling capacity, drug content estimation, rheological study, in vitro diffusion study, antibacterial activity, isotonicity testing, eye irritation testing. The developed formulations exhibited sustained release of drug from formulation over a period of 6hr thus increasing residence time of the drug. The optimized formulations were tested for eye irritation on albino rabbit (male) using the Draize test protocol with crossover studies. The formulations were found to be non-irritating with no ocular damage or abnormal clinical signs to the cornea, iris or conjunctiva observed. Thus these in situ gelling systems containing gums may be a valuable alternative to the conventional systems.